GSA CAPITAL PARTNERS LLP

Position in ARVN — Arvinas, Inc.

CIK 1362033 LONDON, X0

Position in ARVN

as of Jun 30, 2026 · filed Aug 6, 2026 Compact

Position Value

$1,181,798

-$230,673 QoQ

Shares Held

142,214

+6.7% QoQ

Ownership

0.217%

of shares outstanding

% of Portfolio

0.08%

of 13F equity value

Holder Rank

#50

of 198 holders

Holding Since

Jun 2020

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. ARVN ranks #27 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IOVA	Iovance Biotherapeutics, Inc.	655,318	$2,726,122
2	IMVT	Immunovant, Inc.	65,267	$2,514,737
3	GOSS	Gossamer Bio, Inc.	14,986,947	$2,472,846
4	AXSM	Axsome Therapeutics, Inc.	9,419	$2,305,488
5	CABA	Cabaletta Bio, Inc.	668,563	$2,079,230
6	MLTX	MoonLake Immunotherapeutics	106,695	$2,077,351
7	ATYR	aTYR PHARMA INC	3,454,863	$2,062,553
8	CORT	Corcept Therapeutics Inc	23,257	$2,022,196

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,181,798	142,214	+6.7%	Shares	Sole	2026-08-06
2026-03-31	$1,412,471	133,252	+216.5%	Shares	Sole	2026-05-08
2025-12-31	$499,282	42,098	+185.3%	Shares	Sole	2026-02-06
2025-09-30	$125,712	14,755	-38.2%	Shares	Sole	2025-11-07
2025-06-30	$175,653	23,866	+75.4%	Shares	Sole	2025-07-22
2025-03-31	$95,493	13,603	-0.3%	Shares	Sole	2025-05-08
2023-06-30	$338,768	13,649	+73.3%	Shares	Sole	2023-08-14
2021-09-30	$647,167	7,875	-28.9%	Shares	Sole	2021-11-12
2021-06-30	$852,621	11,073	+63.1%	Shares	Sole	2021-08-05
2021-03-31	$448,885	6,791	-31.2%	Shares	Sole	2021-05-10
2020-12-31	$838,089	9,868	-10.3%	Shares	Sole	2021-02-03
2020-09-30	$259,662	10,998	+47.3%	Shares	Sole	2020-11-06
2020-06-30	$250,476	7,468	—	Shares	Sole	2020-08-11
No filing history on record for this holder in this stock.